by Sean Quinn | Aug 3, 2022 | Article
Source: KPS Life Outsourcing trends are shifting rapidly in the drug development sector as it has become apparent that Functional Service Provider (FSP) outsourcing versus a full-service CRO model can deliver demonstrated cost savings in terms of operational...
by Sean Quinn | Aug 3, 2022 | Article
Contributors: Adrian Otte, KPS Life & Patty Leuchten, WCG Avoca Outsourcing has become increasingly popular in the biopharmaceutical space, driven by enhanced cost savings, improved timetables, and streamlined risk management. While the rates at which biopharma’s...
by Sean Quinn | Aug 3, 2022 | Article
By Dr. Armand Czaplinski and Kevin Duffy, KPS Life The COVID-19 pandemic has impacted every industry in a variety of ways. For biopharmaceutical companies, this impact has been as comprehensive as it has been intense, affecting everything from the supply chains for...
by Sean Quinn | Nov 17, 2021 | Article
Author: Kevin Duffy, Chief Commercial Officer There is continuous evaluation and varying opinion regarding the strategic resourcing models employed within the biopharmaceutical sector today. Notwithstanding the recent hurdles of COVID-19, understanding the human...
by George Sawicki | Nov 25, 2019 | Article
Co-Monitoring Visits (Monitoring Oversight) Sponsors and CROs employ CRAs to monitor clinical study sites. Because most site monitoring is done in the field, it is challenging for study managers to know and understand if CRAs/monitors are conducting their duties...
